U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H18F3N3O6
Molecular Weight 441.3587
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ANDARINE

SMILES

CC(=Nc1ccc(cc1)OC[C@@](C)(C(=Nc2ccc(c(c2)C(F)(F)F)N(=O)=O)O)O)O

InChI

InChIKey=YVXVTLGIDOACBJ-SFHVURJKSA-N
InChI=1S/C19H18F3N3O6/c1-11(26)23-12-3-6-14(7-4-12)31-10-18(2,28)17(27)24-13-5-8-16(25(29)30)15(9-13)19(20,21)22/h3-9,28H,10H2,1-2H3,(H,23,26)(H,24,27)/t18-/m0/s1

HIDE SMILES / InChI

Molecular Formula C19H18F3N3O6
Molecular Weight 441.3587
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15308613 http://adisinsight.springer.com/drugs/800019485

Andarine is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc for treatment of conditions such as muscle wasting, osteoporosis and benign prostatic hypertrophy. Andarine is a selective non-steroidal androgen receptor (AR) agonist with Ki of 4 nM, tissue-selective for anabolic organs. Andarine had been in phase I clinical trials by GTx for the treatment of cancer-related cachexia and osteoporosis. However, this research has been discontinued.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
4.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit.
2009 Jun 25
Patents

Sample Use Guides

Dogs: An intravenous (i.v.) bolus dose of 10 or 3 mg/kg, an oral(p.o.) solution dose of 10 mg/kg, or an oral capsule dose of 10 mg/kgadministered in a packed gelatin capsule
Route of Administration: Other
Andarine stimulates AR-mediated transcription to 93% of that observed for 1 nM DHT at a concentration of 10 nM.
Substance Class Chemical
Created
by admin
on Fri Jun 25 23:10:11 UTC 2021
Edited
by admin
on Fri Jun 25 23:10:11 UTC 2021
Record UNII
7UT2HAH49H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ANDARINE
Common Name English
GTX-007
Code English
PROPANAMIDE, 3-(4-(ACETYLAMINO)PHENOXY)-2-HYDROXY-2-METHYL-N-(4-NITRO-3-(TRIFLUOROMETHYL)PHENYL)-, (2S)-
Systematic Name English
Classification Tree Code System Code
DSLD 4029 (Number of products:6)
Created by admin on Fri Jun 25 23:10:11 UTC 2021 , Edited by admin on Fri Jun 25 23:10:11 UTC 2021
Code System Code Type Description
DRUG BANK
DB07423
Created by admin on Fri Jun 25 23:10:11 UTC 2021 , Edited by admin on Fri Jun 25 23:10:11 UTC 2021
PRIMARY
EPA CompTox
401900-40-1
Created by admin on Fri Jun 25 23:10:11 UTC 2021 , Edited by admin on Fri Jun 25 23:10:11 UTC 2021
PRIMARY
FDA UNII
7UT2HAH49H
Created by admin on Fri Jun 25 23:10:11 UTC 2021 , Edited by admin on Fri Jun 25 23:10:11 UTC 2021
PRIMARY
CAS
401900-40-1
Created by admin on Fri Jun 25 23:10:11 UTC 2021 , Edited by admin on Fri Jun 25 23:10:11 UTC 2021
PRIMARY
WIKIPEDIA
ANDARINE
Created by admin on Fri Jun 25 23:10:11 UTC 2021 , Edited by admin on Fri Jun 25 23:10:11 UTC 2021
PRIMARY
PUBCHEM
9824562
Created by admin on Fri Jun 25 23:10:11 UTC 2021 , Edited by admin on Fri Jun 25 23:10:11 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> AGONIST
BINDING
Related Record Type Details
ACTIVE MOIETY